INTRODUCTION
Monosodium urate crystals initiate gouty inflammation. Several lines of evidence have implicated the complement system in this process. For example, prior complement depletion in rats (1) and dogs (2) Receivedfor publication 22 September 1978 and in revised form 8 December 1978. components, C2 to C5. These workers suggested that urates activate complement via a novel pathway, because Cl was only slightly depleted. One purpose of this study was to determine a mechanism by which the components of the classical complement pathway might be activated by urate crystals.
It is known that urate crystals avidly bind immunoglobulin(G) when exposed to serum (5) . This suggests the possibility that adsorbed immunoglobulin might be responsible for activation of complement by urate crystals in serum. Although Naff and Byers (3) reported that urate crystals also activated complement in immunoglobulin-deficient sera, the presence of minor quantities of contaminating immunoglobulin could not be excluded. The purpose of this study was thus twofold. First, we wanted to determine to what extent urate crystals could activate Cl, either in serum or in purified form, and second, whether IgG might be required for the observed Cl activation.
METHODS
Urate crystals. Uric acid crystals (ICN Pharmaceuticals Inc., Cleveland, Ohio) were heated at 200°C for 2 h to destroy possible pyrogens. These crystals were then slowly neutralized under aseptic conditions with 0.1 M NaOH in sterile nonpyrogenic water in glassware that had been heated 200°C for 2 h as described (6) . The monosodium urate crystals produced were negatively birefringent needleshaped, and showed an x-ray powder diffraction pattern typical of monosodium urate monohydrate (7) . Culture of the crystal suspension yielded no bacterial growth. Crystals were stored at -20°C at 25 mg/ml, and thawed once before use.
Reagents and proteins. Sodium dodecyl sulfate (SDS),' acrylamide, and dithiothreitol were purchased from Sigma 'Abbreviations used in this paper: SDG, sucrose density gradient; SDS, sodium dodecyl sulfate; SDS-PAGE, SDS polyacrylamide gel electrophoresis. Chemical Co. (St. Louis, Mo.) and Bio-Rad Laboratories (Richmond, Calif.). Precursor forms of Clq, Clr, and Cls were purified from normal human serum by published methods (8) (9) (10) . Human immunoglobulin (IgG) was prepared by DEAE cellulose chromatography of dialyzed human serum (0.01 M phosphate buffer, pH 7.4) and was heat aggregated at 63°C for 15 min. Cls was radiolabeled with Na 1251 (carrier free, New England Nuclear, Boston, Mass.) using lactoperoxidase-coupled Sepharose beads (Pharmacia Fine Chemicals, Piscataway, N. J.) as described (11) . F(ab')2 fragments of goat anti-human Fc antibody were prepared as published (12) .
Reconstitution of macromolecular proenzyme Cl. Cl was reconstituted from highly purified Clq, proenzyme Clr, and '251-labeled proenzyme Cls in the presence of calcium as described (11) .
SDS polyacrylamide gel electrophoresis (SDS-PAGE). Experiments were performed with a modification (9) of the method of Weber and Osborn (13) . After electrophoresis, gels were sectioned at 2-mm intervals and analyzed for radioactivity.
Sucrose density gradient (SDG) ultracentrifugation. SDG studies were carried out in 9-31% linear sucrose gradients in barbital-buffered saline containing 1.5 x 0.1 mM calcium chloride (14) exactly as published (15) .
Complement and complement component measurements. Complement and Cl, C3 (16) , and C4 (17) measurements were carried out by standard hemolytic techniques.
Cl binding assays. Binding of Cl to urate crystals was assessed directly, with SDG ultracentrifugation. This technique was chosen because it permits not only direct measurement of Cl binding but also detects Cl that has been activated and has dissociated from the activator (18) . Varying amounts of urate crystals in S ,ul vol were incubated for 10 min at 0°C with 8 ,ug of Clq and 4 ,ug each of Clr and 125I-Cls in a total volume of 20-30 ,ul in 0.05 M Tris, pH 7.5 containing 0.1 M NaCl and 0.005 M calcium resulting in the formation of 5 ,ug Cl macromolecule plus remaining free subcomponents. The mixtures were then subjected to SDG as described above. The proportion of radioactivity in the 16 S peak and on the bottom of the tubes was taken as total-Cl for calculating the percentage bound (bottom) in the control and experimental samples.
Cl activation assays. Determination of Cl activation was carried out by procedures that have been published (11) . In brief, reconstituted Cl was further purified by SDG ultracentrifugation and the gradient fractions collected at 0°C into tubes chilled in an ice bath. The 16 S area of the gradient was pooled and frozen in aliquots at -70°C. Activation analyses were carried out by incubating experimental samples with reconstituted 125I-Cls-labeled Cl. Each aliquot contained 0.2-1.0 ,ug of Cl, and the total volume of the activation reaction mixture was 25-50 ,ul. Negative controls lacking activator but containing urate-saturated buffer and positive controls conitaining 10 ug of aggregated IgG or 5 ,ug of lipopolysaccharide (strain R 595) (15) were routinely included. After incubation for 20 min at 30°C, SDS, urea, and dithiothreitol were added and the mixtures analyzed by SDS-PAGE. Because all of the radiolabel appears in either the proenzyme 87,000-dalton peak or the 59,000-dalton peak of the heavy chain of Cls, quantitation of Cl activation by the various activators was achieved by determining the percentage of total radioactivity transferred to the 59,000-dalton peak of the heavy chain of Cls, after correcting for spontaneous Cls activation in the sample containing uratesaturated buffer. Urate-saturated buffer alone did not activate Cl in comparison to the same buffer without dissolved urate.
RESULTS
Complement activation by urate crystals in serum.
To determine the extent to which urate crystals would deplete serum complement, varying amounts of crystals were incubated in serum for 30 min at 37°C. Hemolytic assays for Cl, C4, C3, and CH50 were performed on the serum after the crystals had been removed by centrifugation. Complement depletion by 20 mg/ml of crystals in serum is shown in Fig. 1 .
The pattern of depletion observed, with proportionate reductions of CHso and of Cl, C4, and also C3 is indicative of classical pathway activation. As shown in the dose-response experiment depicted in Fig. 2, CH50 , Cl and C3 activities were progressively depleted as the dose of crystals added to serum was increased. Thus, the CH50, Cl, and C3 activities were reduced 57, 52, and 46%, respectively, after incubation of serum with 10 mg/ml of crystals.
Cl binding by urate crystals. The reduction in Cl levels observed in the above studies (Figs. 1 and 2) suggested that Cl bound to urate crystals. To further evaluate this possibility, urate crystals were incubated for 10 min at 0°C with reconstituted macromolecular Cl that had been formed from highly purified immunoglobulin-free Clq, proenzyme Clr, and 1251-labeled proenzyme Cls during 10 min of incubation at 0°C in the presence of calcium as described (11) . Cl binding was appraised and quantitated by sucrose density gradient ultracentrifugation. As shown in Table I Lack of participation of endotoxin in complement activation by monosodium urate crystals. The uric acid crystals were originally heated at 200°C before neutralization with NaOH to destroy possible pyrogens, and then frozen in small aliquots that were thawed once just before use. Several tests were performed to further rule out the participation of lipopolysaccharide in the complement activation observed in these results. The crystals were dissolved in sterile NaCl at 100°C at a concentration of 0.1 mg/ml and 50 ml was infused intravenously into rabbits. Neither temperature elevation nor neutropenia resulted, indicating that the crystals contained <50 ng of bacterial lipopolysaccharide per 5 mg of urate crystals (19) . Also, bacteriologic cultures of the crystals were sterile. In another approach, sodium urate crystals were heated at 200°C for 2 h to destroy potential pyrogens and then reexamined for complement activating ability. As shown in Table II anti-Fc antibody used, 15 ,ug, completely blocked Cl activation by 10 gg ofaggregated humlan IgG. However, the F(ab')2 aniti-Fc antibody had n1o effect on the Cl activatiing ability of the urate crystals. Because of the biphasic relationship between the dlose of urate crystals and(l C1 activation (Fig. 4) , it was important to study the effect of F(ab')2 aniti-Fc antibody on (loses of crystals producing submaximal activation. As shown in Table  III , in this experiment, 3 ,ug of urate crystals produced only 33% of the maximiial amount of Cl activation. 15 Asg F(ab')2 acnti-Fc antibodv had no effect on Cl activation even at this low crystal dlose. Thus, we conclude that IgG is niot re(juire(I for Cl activationi b)y urate crystals.
DISCUSSION
These studies indicate that urate crystals can activate the classical pathway of complement when added to serum. In our experiments, 10 mg urate crystals/ml produced 57% reduction of CH50. For comparison, in experimental gout (20), crystal concenitrations of _7.5 mig/mil in(duce inflaiiimmationi in caninle stifle joints. Although comnplement activationi by uratte crystals has l)een dlemonstrated (3, 4, 21) , and (lepression of C4, C2, and C3 levels was described (3), indicating classical pathway activation, the exact mechanism was not resolved. The marked depression of C4, C2, and C3 levels with little alteration in Cl titers observed by Naff and Bvers (3) ledl them to postulate a niovel mechaniismi of The pattern of complement component consumption observed in our studies, with marked Cl, C4, and C3 depletion is typical of classical pathway activation. We thus have no explanation for the failure of Naff and Byers (3) to observe a reduction in C 1 levels proportionate to the reduction in C4, C2, and C3 levels. In addition, in our studies, urate crystals were found to directly activate isolated macromolecular C1, further indicating that urates can activate complement via Cl. Furthermore, activation by urate crystals required intact macromolecular Cl, as no Cls activation occurred when omitting Clq or Clr or both components. Thus, Cl activation by urate crystals does not involve direct activation of Clr or Cls by the crystals as observed with univalent 2,4-dinitrophenol-polylysine-antibody complexes (22) and certain enzymes such as plasmin (23) . It is most likely, therefore, that urate crystals, like most activators, activate Cl via an initial interaction with Clq followed by sequential Clr and Cls activation. We thus find no evidence for another pathway ofactivation distinct from the classical and alternative pathways.
There has been some concern that possible bacterial lipopolysaccharide contamination of urate preparations might be involved in complement activation by urate crystals. Both Phelps and McCarty (21) and Naff and Byers (3) reported that urate crystals heated at 200°C for 2 h, to destroy possible contaminating pyrogens, consumed less complement than unheated crystals. However, complement consuming activity was regained in Naff and Byers' studies (3) when the heated crystals were dissolved and reformed, providing evidence against lipopolysaccharide mediation of the complement consumption. In our studies, we also found that (15) . The reasons for this type of inhibition are not clear but are presumably related to steric effects.
Urate crystals avidly bind IgG (5) and are probably coated with immunoglobulin in vivo. Naffand Byers (3) showed that urate crystals could deplete complement activity in most immunoglobulin deficient sera. Our studies show that IgG is not necessary for efficient Cl activation by urate crystals. Not only did urate crystals bind and also activate immunoglobulin-free macromolecular Cl, but Cl activation by urate crystals proceeded unimpaired in the presence of F(ab')2 fragments of anti-human Fc antibody. In the same experiments, the F(ab')2 anti-Fc completely blocked Cl activation by aggregated IgG.
The data presented in this paper have defined the mechanism bv which monosoclium urate crystals, the etiologic agent of gout, activate the complement system. Efficient immunioglobulin-independent activation of the classical pathway supports the hypothesis (3) that activation of complemiient directly contributes to the acute inflammatory response of gout.
